Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Saturday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Up 53.2 %

CHEK opened at $1.77 on Friday. Check-Cap has a twelve month low of $0.56 and a twelve month high of $3.45. The firm has a market cap of $10.36 million, a price-to-earnings ratio of -0.59 and a beta of 0.25. The company has a fifty day simple moving average of $0.95 and a 200 day simple moving average of $1.51.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.